These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31430072)

  • 21. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
    Tsujita K; Yamanaga K; Komura N; Sakamoto K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    Eur J Prev Cardiol; 2016 Sep; 23(14):1524-8. PubMed ID: 27296705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol.
    Niedzielski M; Broncel M; Gorzelak-Pabiś P; Woźniak E
    PLoS One; 2021; 16(9):e0256996. PubMed ID: 34492054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients.
    Cerda A; Rodrigues AC; Alves C; Genvigir FD; Fajardo CM; Dorea EL; Gusukuma MC; Pinto GA; Hirata MH; Hirata RD
    Cardiovasc Ther; 2015 Aug; 33(4):168-76. PubMed ID: 25903419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
    Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR
    Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque.
    Meng X; Zhang K; Li J; Dong M; Yang J; An G; Qin W; Gao F; Zhang C; Zhang Y
    Mol Med; 2012 May; 18(1):598-605. PubMed ID: 22331026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME.
    Japaridze L; Sadunishvili M; Megreladze I
    Georgian Med News; 2016 Mar; (252):15-22. PubMed ID: 27119829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
    Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease.
    Jia L; Zhu L; Wang JZ; Wang XJ; Chen JZ; Song L; Wu YJ; Sun K; Yuan ZY; Hui R
    Atherosclerosis; 2013 Jun; 228(2):346-52. PubMed ID: 23566804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque　- The ZIPANGU Study.
    Ueda Y; Hiro T; Hirayama A; Komatsu S; Matsuoka H; Takayama T; Ishihara M; Hayashi T; Saito S; Kodama K;
    Circ J; 2017 Oct; 81(11):1611-1619. PubMed ID: 28592751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells.
    Genvigir FD; Rodrigues AC; Cerda A; Hirata MH; Curi R; Hirata RD
    Drug Metabol Drug Interact; 2011; 26(1):33-6. PubMed ID: 21417795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Levels of IL-35 and Gene Expression of FoxP3 in Coronary Artery Disease: Is There Any Interplay Between Them and 25-Hydroxyvitamin D3?
    Shateri H; Fadaei R; Najafi M; Vatannejad A; Teimouri M; Zali F; Emamgholipour S; Parvaz E; Asadnia M; Doosti M
    Clin Lab; 2018 Apr; 64(4):483-490. PubMed ID: 29739077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment.
    Wang ZX; Wang CQ; Li XY; Ding Y; Feng GK; Jiang XJ
    Int Heart J; 2015; 56(2):163-9. PubMed ID: 25740578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression.
    Tabuchi T; Satoh M; Itoh T; Nakamura M
    Clin Sci (Lond); 2012 Aug; 123(3):161-71. PubMed ID: 22364258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse.
    Ai C; Zhang S; He Q; Shi J
    Lipids Health Dis; 2018 Oct; 17(1):239. PubMed ID: 30326894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.